Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)

Historic Common Equity for Anbio Biotechnology (NNNN) over the last 3 years, with Q2 2025 value amounting to $27549.5 billion.

  • Anbio Biotechnology's Common Equity changed N/A to $27549.5 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $27549.5 billion, marking a year-over-year change of. This contributed to the annual value of $17191.6 billion for FY2024, which is 11601237558.15% up from last year.
  • As of Q2 2025, Anbio Biotechnology's Common Equity stood at $27549.5 billion.
  • Anbio Biotechnology's 5-year Common Equity high stood at $27549.5 billion for Q2 2025, and its period low was $14.8 million during Q4 2023.
  • Moreover, its 3-year median value for Common Equity was $17191.6 billion (2024), whereas its average is $14913.7 billion.
  • The largest annual percentage gain for Anbio Biotechnology's Common Equity in the last 5 years was 11601237558.15% (2024), contrasted with its biggest fall of 11601237558.15% (2024).
  • Quarter analysis of 3 years shows Anbio Biotechnology's Common Equity stood at $14.8 million in 2023, then soared by 116012375.58% to $17191.6 billion in 2024, then skyrocketed by 60.25% to $27549.5 billion in 2025.
  • Its Common Equity stands at $27549.5 billion for Q2 2025, versus $17191.6 billion for Q4 2024 and $14.8 million for Q4 2023.